Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

被引：474

作者：

Ducry, Laurent ^{[1
]}

Stump, Bernhard ^{[1
]}

机构：

[1] Lonza Ltd, CH-3930 Visp, Switzerland

来源：

BIOCONJUGATE CHEMISTRY | 2010年 / 21卷 / 01期

关键词：

ACUTE MYELOID-LEUKEMIA; TARGETED CANCER-THERAPY; ANTITUMOR-ACTIVITY; CALICHEAMICIN CONJUGATE; BIOLOGICAL EVALUATION; SELECTIVE TREATMENT; ANTIBIOTIC CC-1065; LINKER STABILITY; IN-VIVO; POTENT;

D O I：

10.1021/bc9002019

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.

引用

收藏

页码：5 / 13

页数：9

相关论文

共 51 条

[11] Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity [J].

Doronina, SO ;

Mendelsohn, BA ;

Bovee, TD ;

Cerveny, CG ;

Alley, SC ;

Meyer, DL ;

Oflazoglu, E ;

Toki, BE ;

Sanderson, RJ ;

Zabinski, RF ;

Wahl, AF ;

Senter, PD .

BIOCONJUGATE CHEMISTRY, 2006, 17 (01) :114-124

[12] Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].

Doronina, SO ;

Toki, BE ;

Torgov, MY ;

Mendelsohn, BA ;

Cerveny, CG ;

Chace, DF ;

DeBlanc, RL ;

Gearing, RP ;

Bovee, TD ;

Siegall, CB ;

Francisco, JA ;

Wahl, AF ;

Meyer, DL ;

Senter, PD .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784

[13] Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate [J].

Doronina, Svetlana O. ;

Bovee, Tim D. ;

Meyer, David W. ;

Miyamoto, Jamie B. ;

Anderson, Martha E. ;

Morris-Tilden, Carol A. ;

Senter, Peter D. .

BIOCONJUGATE CHEMISTRY, 2008, 19 (10) :1960-1963

[14] Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity [J].

Dubowchik, GM ;

Firestone, RA ;

Padilla, L ;

Willner, D ;

Hofstead, SJ ;

Mosure, K ;

Knipe, JO ;

Lasch, SJ ;

Trail, PA .

BIOCONJUGATE CHEMISTRY, 2002, 13 (04) :855-869

[15] Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing [J].

Erickson, HK ;

Park, PU ;

Widdison, WC ;

Kovtun, YV ;

Garrett, LM ;

Hoffman, K ;

Lutz, RJ ;

Goldmacher, VS ;

Blättler, WA .

CANCER RESEARCH, 2006, 66 (08) :4426-4433

[16] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].

Francisco, JA ;

Cerveny, CG ;

Meyer, DL ;

Mixan, BJ ;

Klussman, K ;

Chace, DF ;

Rejniak, SX ;

Gordon, KA ;

DeBlanc, R ;

Toki, BE ;

Law, CL ;

Doronina, SO ;

Siegall, CB ;

Senter, PD ;

Wahl, AF .

BLOOD, 2003, 102 (04) :1458-1465

[17] A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts [J].

Hamann, PR ;

Hinman, LM ;

Beyer, CF ;

Lindh, D ;

Upeslacis, J ;

Shochat, D ;

Mountain, A .

BIOCONJUGATE CHEMISTRY, 2005, 16 (02) :354-360

[18] An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker [J].

Hamann, PR ;

Hinman, LM ;

Beyer, CF ;

Lindh, D ;

Upeslacis, J ;

Flowers, DA ;

Bernstein, I .

BIOCONJUGATE CHEMISTRY, 2002, 13 (01) :40-46

[19] Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia [J].

Hamann, PR ;

Hinman, LM ;

Hollander, I ;

Beyer, CF ;

Lindh, D ;

Holcomb, R ;

Hallett, W ;

Tsou, HR ;

Upeslacis, J ;

Shochat, D ;

Mountain, A ;

Flowers, DA ;

Bernstein, I .

BIOCONJUGATE CHEMISTRY, 2002, 13 (01) :47-58

[20] Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate [J].

Hamblett, KJ ;

Senter, PD ;

Chace, DF ;

Sun, MMC ;

Lenox, J ;

Cerveny, CG ;

Kissler, KM ;

Bernhardt, SX ;

Kopcha, AK ;

Zabinski, RF ;

Meyer, DL ;

Francisco, JA .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :7063-7070

← 1 2 3 4 5 6 →